Humanities › History & Culture Who Developed the Polio Vaccine? Share Flipboard Email Print Child receiving oral polio vaccine. Getty Images/Moment/Ramesh Lalwani History & Culture Inventions Famous Inventions Famous Inventors Patents & Trademarks Invention Timelines Computers & The Internet American History African American History African History Ancient History and Culture Asian History European History Genealogy Latin American History Medieval & Renaissance History Military History The 20th Century Women's History View More By Tuan C. Nguyen Updated November 28, 2017 Shortly before the turn of the 20th century, the first case of paralytic polio in the United States was reported in Vermont. And what had begun as a health scare would, over the next several decades, turn into a full-blown epidemic as the virus known as infantile paralysis spread among children across the country. In 1952, the height of the hysteria, there were as many as 58,000 new cases. A Summer of Fear It was undoubtedly a scary time back then. The summer months, normally a relaxing time for many youths, was considered polio season. Children were warned to stay away from swimming pools because they could easily catch the disease by going into infected waters. And in 1938, President Franklin D. Roosevelt, who was infected at age 39, helped create the National Foundation for Infantile Paralysis in an effort to combat the disease. Jonas Salk, Father of the First Vaccine In the late 1940's, the foundation began sponsoring the work of a researcher at the University of Pittsburgh named Jonas Salk, whose biggest achievement to date was the development of a flu vaccine that used killed viruses. Normally, weakened versions were injected to cause the immune system to produce antibodies capable of recognizing and killing the virus. Salk was able to categorize the 125 strains of the virus under three basic types and wanted to see if the same approach would also work against the Polio virus. Up to this point, researchers weren’t making progress with live viruses. Dead viruses also offered the key advantage of being less dangerous since it wouldn’t lead to inoculated people accidentally getting the disease. The challenge, though, was to be able to manufacture enough of these dead viruses to mass produce the vaccines. Fortunately, a method for making dead viruses in large quantities was discovered just a few years earlier when a team of Harvard researchers figured out how to grow them inside animal-cell tissue cultures rather than having to inject a live host. The trick was using penicillin to prevent bacteria from contaminating the tissue. Salk’s technique involved infecting monkey kidney cell cultures and then killing the virus with formaldehyde. After successfully testing the vaccine in monkeys, he began trialing the vaccine in humans, which included himself, his wife and children. And in 1954, the vaccine was field tested in almost 2 million children under the age of ten in what was the largest public health experiment in history. The results reported a year later, showed that the vaccine was safe, potent and 90 percent effective in preventing children from contracting polio. There was one hiccup, however. Administration of the vaccine was momentarily shut down after 200 people were found to have gotten polio from the vaccine. The researchers were eventually able to trace the adverse effects to a defective batch made by one drug company and vaccination efforts resumed once revised production standards were established. Sabin vs. Salk: Rivals for a Cure By 1957, the cases of new polio infections had dwindled done to under 6,000. Yet despite the dramatic results some experts still felt that Salk’s vaccine was insufficient in fully inoculating people against the disease. One researcher in particular named Albert Sabin argued that only an attenuated live-virus vaccine would confer lifetime immunity. He had been working on developing such a vaccine around the same time and was figuring out a way for it to be taken orally. While the United States backed Salk’s research, Sabin was able to get support from the Soviet Union to conduct trials of an experimental vaccine that used a live strain on the Russian population. Like his rival, Sabin also tested the vaccine on himself and his family. Despite a slight risk of vaccinations resulting in Polio, it was proven to be effective and cheaper to manufacture than Salk’s version. The Sabin vaccine was approved for use in the U.S. in 1961 and would later replace the Salk vaccine as the standard for preventing Polio. But even to this day, the two rivals never did settle the debate over who had the better vaccine. Salk always maintained that his vaccine was the safest and Sabin would not concede that injecting a killed virus can be as effective as conventional vaccines. In either case, both scientists played a crucial role in nearly eradicating what was once a devastating condition.